tbuckley/cabot-search huggingface dataset:
OP0322-PARE HOW TO COMMUNICATE DIAGNOSTIC INFORMATION AND CUTTING EDGE SCIENCE TO PATIENTS WITH RHEUMATIC DISEASES
Authors: I. Loell, S. Jansson, J. Hammarström, L. Alemo Munters
Journal: Annals of the Rheumatic Diseases (2020)

Background: According to the 2017 Swedish Rheumatology Association (SRA) member strategy a recurring member survey as well as a member withdrawal survey was stipulated. The strategy was developed to evaluate to what extent SRA fulfills the requirements and expectations of its members. According to the 2019 survey, the most important output from a SRA membership, the members rank information about their diagnosis (#1) and supporting the research of these diagnoses (#2) most valuable. Objectives: To transfer the medical and scientific expertise of the rheumatic diagnoses into lay information in order to meet the member’s needs; to take part of the results of the cutting edge science and research progress, funded by SRA, that are relevant and important to individuals living with rheumatic conditions. Methods: A targeted scientific communication strategy was made consisting of lectures, interviews and scientific writing created for multi-channel distribution. Results: Actions taken upon the survey result Brief summaries of every research project funded by SRA in 2019 was written and distributed via social media. A research day for lay people was arranged in collaboration with a regional SRA branch and invited speakers. The filmed lectures are also available online. A research report with in-depth interviews with researchers and brief summaries about the research funded by SRA was produced. The report was printed and distributed in 70,000 copies to the SRA members, donors and at SRA meetings and conferences. Diagnosis sheets aimed to newly diagnosed patients with the most essential information has been developed in collaboration with a patient research partner and an expert researcher within the field. The sheet is printable and can be distributed by any healthcare practitioner or by patients/public. Online patient school prototype - gout. In collaboration with the SRA funded gout network we are gathering high quality information about the diagnosis, treatment, self-care and support in the meeting with the healthcare provider for patients to easily navigate and to find robust answers to their inquiries about their disease. Conclusion: As a member of SRA, regardless of rheumatic disease, the main interest is knowing more about their diagnosis and about the ongoing research in the field. Through collaborations and communicating rheumatic conditions and research within the field in lay language the patients can experience self-empowerment and the need for patient education can be met. Disclosure of Interests: None declared
Bacteriolytic Therapy: Tumor Microenvironment Targeting Nano–Bio Emulsion for Synergistic Combinational X‐Ray PDT with Oncolytic Bacteria Therapy (Adv. Healthcare Mater. 13/2020)
Authors: Wooram Park, Soojeong Cho, Dongkyu Kang, Jun‐Hyeok Han, Jung‐Hoon Park, Byeongdu Lee, Joonseok Lee, Dong‐Hyun Kim
Journal: Advanced Healthcare Materials (2020)

In article number 1901812 by Joonseok Lee, Dong-Hyun Kim, and co-workers, a tumor microenvironment targeting nano-bio therapeutic emulsion formulated with multi-functional nanoscintillators and anaerobic C. novyi-NT spores is developed for synergistic combinational cancer therapy. Nano-bio therapeutic emulsion is delivered to tumor sites under CT-image guidance, and effectively treats the normoxic peripheral and hypoxic central tumor region.
Xenogeneic cross-circulation for extracorporeal recovery of injured human lungs
Authors: Ahmed E. Hozain, John D. O’Neill, Meghan R. Pinezich, Yuliya Tipograf, Rachel Donocoff, Katherine M. Cunningham, Andrew Tumen, Kenmond Fung, Rei Ukita, Michael T. Simpson, Jonathan A. Reimer, Edward C. Ruiz, Dawn Queen, John W. Stokes, Nancy L. Cardwell, Jennifer Talackine, Jinho Kim, Hans-Willem Snoeck, Ya-Wen Chen, Alexander Romanov, Charles C. Marboe, Adam D. Griesemer, Brandon A. Guenthart, Matthew Bacchetta, Gordana Vunjak-Novakovic
Journal: Nature Medicine (2020)
P-68 Safety and tolerability of a novel combination regimen OXIRI and its immunomodulatory effect in Asian pancreatic ductal adenocarcinoma patients
Authors: S. Chen, W. Ong, S. Lee, A. Seet, D. Tai, S. Choo, M. Ng, S. Biswas, B. Chowbay
Journal: Annals of Oncology (2020)
Abstract 17285: Trends and Outcomes of Fibrinolytic Therapy in Patients With Pulmonary Embolism and Metastatic Cancer
Authors: Gbolahan O Ogunbayo, Robert Pecha, Naoki Misumida, Karam Ayoub, Dustin Hillerson, Ahmed Abdel-latif, Claude S Elayi, Adrian W Messerli, Susan S Smyth
Journal: Circulation (2018)

Introduction: Pulmonary embolism in the setting of cancer portends a poor prognosis. There is limited data on the use and outcomes of fibrinolytic therapy (FT) in this subgroup of patients. This study describes temporal trends and outcomes of the use of FT among these patients. Hypothesis: The use of FT in patients with metastatic cancer and acute pulmonary embolism is associated with higher mortality Methods: Using the NIS database, we extracted patients with metastatic cancer admitted with a primary diagnosis of acute pulmonary embolism from January 2010 to December 2014. Using weighted data we analyzed the trends of FT in these patients. For analysis of outcomes, we performed a propensity score matching (match tolerance.01) of patients with PE and FT. After matching, we compared baseline characteristics and inpatient outcomes of patients with PE who underwent FT with those that did not. Or primary outcome was mortality. We performed a multivariable regression analysis with mortality as our outcome. We also described predictors of mortality in patients that underwent FT. Results: Of the 65,882 patients with metastatic cancer admitted with a primary diagnosis of PE, 946 (1.4%) underwent fibrinolytic therapy. There was a significant trends of increase in the use of FT in this cohort of patients, increasing from 0.9% in 2010 to 2.1% in 2014. After exclusions 666 were included in the propensity match and all were matched. Both groups were well matched with regards to baseline characteristics. Patients with FT were less likely to be Caucasian or have anemia. The use of FT was more common in teaching hospitals. Patients in the FT arm were more likely to have cardiac arrest, respiratory failure and acute renal failure. There was no difference in rates of bleeding or blood transfusion. Mortality was significantly higher in the FT arm (24% vs. 1.6%, p&lt;.01). In multivariable analysis, FT was independently associated with mortality (OR 8.35, 95% CI 2.2-32.94; p&lt;.01). Among patients with metastatic cancer and acute PE that underwent FT, independent predictors of mortality were Obesity (OR 4.51, 95% CI 1.35-15.03; p=.02), history of coagulopathy (OR 6.71, 95% CI 1.35-33.46; p=.02), current tobacco abuse (OR 3.26, 95% CI 1.04-10.21; p=.04) and a history of anticoagulant use (OR 2.21, 95% CI 1.02-4.82; p=.046). Conclusions: Fibrinolytic therapy in patients with metastatic cancer and acute pulmonary embolism is associated with increase mortality. The clinical benefits expected from the use fibrinolytic therapy in these patients should be weighed against the risks.
P-25 Single-institution experience of total neoadjuvant therapy for locally advanced rectal cancer: Long-term results
Authors: C. Spatola, G. Privitera, R. Milazzotto, R. Liardo, V. Salamone, L. Raffaele, P. Foti, A. Basile, S. Palmucci, A. Licata, A. Di Cataldo, A. Amico, G. Acquaviva, G. Li Destri
Journal: Annals of Oncology (2020)
miR-125a-5p regulates megakaryocyte proplatelet formation via the actin-bundling protein L-plastin
Authors: Seema Bhatlekar, Bhanu K. Manne, Indranil Basak, Leonard C. Edelstein, Emilia Tugolukova, Michelle L. Stoller, Mark J. Cody, Sharon C. Morley, Srikanth Nagalla, Andrew S. Weyrich, Jesse W. Rowley, Ryan M. O’Connell, Matthew T. Rondina, Robert A. Campbell, Paul F. Bray
Journal: Blood (2020)
Potential therapeutic role of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma
Authors: Shijun Yue, Angela Hui, Wei Shi, Nehad Alajez, Simon Green, Sheelagh Frame, Fei-Fei Liu
Journal: Cancer Research (2008)

5511  Introduction:  Seliciclib is a small molecule CDK inhibitor, with anti-proliferative and anti-tumoral effects, which is currently undergoing evaluation in Phase II clinical trials. No preclinical studies have been undertaken in EBV-positive nasopharyngeal carcinoma (NPC), hence the focus of this work was to evaluate the therapeutic efficacy of seliciclib alone and in combination with ionizing radiation (IR), on the C666-1 NPC model.  Experimental Procedure:  The MTS assay was utilized to measure viability after C666-1 cells were treated with seliciclib + IR. Apoptosis and cell cycle effects were evaluated using flow cytometric analysis. The proportion of cells containing DNA double-strand breaks was assessed using γ-H2AX immunofluorescence. Downstream biochemical effects of seliciclib on Mcl-1 mRNA were assessed using quantitative real time PCR. Therapeutic efficacy of seliciclib + IR was evaluated on established C666-1 tumours implanted in SCID mice.  Results:  Seliciclib reduced viability of C666-1 cells in both a time and dose-dependent manner, with an IC25 of 20 µM. The optimal sequence when combined with IR (4 Gy) was seliciclib treatment first, followed 24 hrs later by IR, which reduced viability down to 20% by day 6. Cell cycle analysis demonstrated accumulation of cells in G2/M, along with a significant increase in the proportion of cells in sub-G1, from 4% under control conditions, up to 14% when treated with both seliciclib (20 µM) and IR (2 Gy), at 72 hrs. This was associated with a increase in caspase-2,-3, -8, -9 activation by 5, 4, 3 and 4-fold respectively, at 48 hrs. Likewise, the proportion of γH2AX-expressing cells post-IR increased to 20% after seliciclib, compared to 14% with IR alone. Quantitative RT-PCR confirmed that seliciclib treatment reduced Mcl-1 transcript levels down to 18% of control, at 72 hrs. In vivo, control mice reached the predefined end-point (tumour and leg diameter 15 mm) at day 15; seliciclib alone prolonged survival by an average of 11 days. Using IR, survival was 57 days, when seliciclib was combined with IR (6 Gy), survival extended to 79 days, with tumour and leg diameter reaching only ~12 mm.  Conclusion:  The NPC model was highly sensitive to seliciclib, with at least an additive interaction when combined with IR, efficiently inducing G2M arrest, apoptosis mediated by caspase activation, along with increased DNA double-strand breaks. Seliciclib combined with IR is also efficacious in vivo, with significant prolongation in survival of tumour-bearing mice, with no discernible toxicity. These data support the evaluation of this combinatorial strategy for human NPC.
Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib
Authors: Jennifer R. Brown, Andrew Zelenetz, Richard Furman, Nicole Lamanna, Anthony Mato, Marco Montillo, Susan O’Brien, Ronald Dubowy, Lin Gu, Veerendra Munugalavadla, Tadeusz Robak, Peter Hillmen
Journal: Leukemia (2020)
O-16 Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and ACHIEVE-2 trials
Authors: T. Yamanaka, T. Yoshino, M. Kotaka, D. Manaka, M. Shiozawa, Y. Sakamoto, Y. Munemoto, T. Eto, K. Shitara, T. Kato, A. Shiomi, J. Hasegawa, A. Makiyama, A. Takagane, M. Nakamura, E. Oki, K. Yamazaki, T. Mizushima, E. Sunami, A. Ohtsu, Y. Maehara, M. Mori
Journal: Annals of Oncology (2020)
Experts protest Trump’s withdrawal from WHO
Authors: Janice Hopkins Tanne
Journal: BMJ (2020)

Some 750 experts in global public health, US constitutional law, and international law and relations have called for leaders in the US Senate and the House of Representatives to prevent the US president, Donald Trump, from withdrawing from the World Health Organization.1

On 9 July WHO’s director general, Tedros Adhanom Ghebreyesus, pleaded with the international community for unity against the covid-19 pandemic, amid a “lack of leadership and solidarity at the global level and national levels.” The pandemic was getting worse and cases had doubled in the past six weeks, he said, urging people to …
SO-14 Baseline diffusion-weighted magnetic resonance imaging features to predict recurrence of anal squamous cell carcinoma following chemoradiotherapy
Authors: K. Owczarczyk, R. Kozarski, A. Qureshi, A. Gaya, M. Siddique, G. Cook, R. Glynne-Jones, V. Goh
Journal: Annals of Oncology (2020)
A Simulation Study to Examine the Information Content in Phylogenomic Data Sets under the Multispecies Coalescent Model
Authors: Jun Huang, Tomáš Flouri, Ziheng Yang
Journal: Molecular Biology and Evolution (2020)

Abstract We use computer simulation to examine the information content in multilocus data sets for inference under the multispecies coalescent model. Inference problems considered include estimation of evolutionary parameters (such as species divergence times, population sizes, and cross-species introgression probabilities), species tree estimation, and species delimitation based on Bayesian comparison of delimitation models. We found that the number of loci is the most influential factor for almost all inference problems examined. Although the number of sequences per species does not appear to be important to species tree estimation, it is very influential to species delimitation. Increasing the number of sites and the per-site mutation rate both increase the mutation rate for the whole locus and these have the same effect on estimation of parameters, but the sequence length has a greater effect than the per-site mutation rate for species tree estimation. We discuss the computational costs when the data size increases and provide guidelines concerning the subsampling of genomic data to enable the application of full-likelihood methods of inference.
P-247 Real-world clinical outcomes for third-line standard of care regimens in deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer in France
Authors: R. Cohen, T. André, M. Roset, M. Amonkar, P. Renna, N. Lara, S. Kothari, D. Tougeron
Journal: Annals of Oncology (2020)
Association of Smoking Cessation and Survival Among Young Adults With Myocardial Infarction in the Partners YOUNG-MI Registry
Authors: David W. Biery, Adam N. Berman, Avinainder Singh, Sanjay Divakaran, Ersilia M. DeFilippis, Bradley L. Collins, Ankur Gupta, Amber Fatima, Arman Qamar, Josh Klein, Jon Hainer, Michael J. Blaha, Marcelo F. Di Carli, Khurram Nasir, Deepak L. Bhatt, Ron Blankstein
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Despite significant progress in primary prevention, the rate of myocardial infarction (MI) continues to increase in young adults. <h3>Objectives</h3> To identify the prevalence of tobacco use and to examine the association of both smoking and smoking cessation with survival in a cohort of adults who experienced an initial MI at a young age. <h3>Design, Setting, and Participants</h3> The Partners YOUNG-MI registry is a retrospective cohort study from 2 large academic centers in Boston, Massachusetts, that includes patients who experienced an initial MI at 50 years or younger. Smoking status at the time of presentation and at 1 year after MI was determined from electronic medical records. Participants were 2072 individuals who experienced an MI at 50 years or younger between January 2000 and April 2016. The dates of analysis were October to December 2019. <h3>Main Outcomes and Measures</h3> Deaths were ascertained from the Social Security Administration Death Master File, the Massachusetts Department of Vital Statistics, and the National Death Index. Cause of death was adjudicated independently by 2 cardiologists. Propensity score–adjusted Cox proportional hazards modeling was used to evaluate the association between smoking cessation and both all-cause and cardiovascular mortality. <h3>Results</h3> Among the 2072 individuals (median age, 45 years [interquartile range, 42-48 years]; 1669 [80.6%] men), 1088 (52.5%) were smokers at the time of their index hospitalization. Of these, 910 patients were further classified into either the cessation group (343 [37.7%]) or the persistent smoking group (567 [62.3%]) at 1 year after MI. Over a median follow-up of 11.2 years (interquartile range, 7.3-14.2 years), individuals who quit smoking had a statistically significantly lower rate of all-cause mortality (hazard ratio [HR], 0.35; 95% CI, 0.19-0.63;<i>P</i> &lt; .001) and cardiovascular mortality (HR, 0.29; 95% CI, 0.11-0.79;<i>P</i> = .02). These values remained statistically significant after propensity score adjustment (HR, 0.30 [95% CI, 0.16-0.56;<i>P</i> &lt; .001] for all-cause mortality and 0.19 [95% CI, 0.06-0.56;<i>P</i> = .003] for cardiovascular mortality). <h3>Conclusions and Relevance</h3> In this cohort study, approximately half of individuals who experienced an MI at 50 years or younger were active smokers. Among them, smoking cessation within 1 year after MI was associated with more than 50% lower all-cause and cardiovascular mortality.
Importance of Paravascular Vitreal Adhesions for Development of Myopic Macular Retinoschisis Detected by Ultra-Widefield OCT
Authors: Hiroyuki Takahashi, Noriko Tanaka, Kosei Shinohara, Kengo Uramoto, Tae Yokoi, Takeshi Yoshida, Kyoko Ohno-Matsui
Journal: Ophthalmology (2020)
Estrogen receptor‐α signaling increases allergen‐induced IL‐33 release and airway inflammation
Authors: Jacqueline‐Yvonne Cephus, Vivek D. Gandhi, Ruchi Shah, Jordan Brooke Davis, Hubaida Fuseini, Jeffrey A. Yung, Jian Zhang, Hirohito Kita, Vasiliy V. Polosukhin, Weisong Zhou, Dawn C. Newcomb
Journal: Allergy (2020)

Abstract Background Group 2 innate lymphoid cells (ILC2) are stimulated by IL‐33 to increase IL‐5 and IL‐13 production and airway inflammation. While sex hormones regulate airway inflammation, it remained unclear whether estrogen signaling through estrogen receptor‐α (ER‐α, Esr1 ) or ER‐β ( Esr2 ) increased ILC2‐mediated airway inflammation. We hypothesize that estrogen signaling increases allergen‐induced IL‐33 release, ILC2 cytokine production, and airway inflammation. Methods Female Esr1 ‐/‐ , Esr2 ‐/‐ , wild‐type (WT), and IL33 fl/fl eGFP mice were challenged with Alternaria extract (Alt Ext) or vehicle for 4 days. In select experiments, mice were administered tamoxifen or vehicle pellets for 21 days prior to challenge. Lung ILC2, IL‐5 and IL‐13 production, and BAL inflammatory cells were measured on day 5 of Alt Ext challenge model. Bone marrow from WT and Esr1 ‐/‐ female mice was transferred (1:1 ratio) into WT female recipients for 6 weeks followed by Alt Ext challenge. hBE33 cells and normal human bronchial epithelial cells (NHBE) were pretreated with 17β‐estradiol (E2), propyl‐pyrazole‐triol (PPT, ER‐α agonist), or diarylpropionitrile (DPN, ER‐β agonist) before allergen challenge to determine IL‐33 gene expression and release, extracellular ATP release, DUOX‐1 production, and necrosis. Results Alt Ext challenged Esr1 ‐/‐ , but not Esr2 ‐/‐ , mice had decreased IL‐5 and IL‐13 production, BAL eosinophils, and IL‐33 release compared to WT mice. Tamoxifen decreased IL‐5 and IL‐13 production and BAL eosinophils. IL‐33eGFP + epithelial cells were decreased in Alt Ext challenged Esr1 ‐/‐ mice compared to WT mice. 17β‐E2 or PPT, but not DPN, increased IL‐33 gene expression, release, and DUOX‐1 production in hBE33 or NHBE cells. Conclusion Estrogen receptor ‐α signaling increased IL‐33 release and ILC2‐mediated airway inflammation.
Tissue-resident memory CD8+ T cells shape local and systemic secondary T cell responses
Authors: Felix M. Behr, Loreto Parga-Vidal, Natasja A. M. Kragten, Teunis J. P. van Dam, Thomas H. Wesselink, Brian S. Sheridan, Ramon Arens, Rene A. W. van Lier, Regina Stark, Klaas P. J. M. van Gisbergen
Journal: Nature Immunology (2020)
Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a
Authors: Sandra Lockmer, Bjorn Ostenstad, Hans Hagberg, Harald Holte, Björn Engelbrekt Wahlin, Chloe Beate Steen, Peter de Nully Brown, Eva Kimby
Journal: Blood (2017)
PD-7 Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer
Authors: P. Pfeiffer, S. Winther, M. Yilmaz, S. Möller, D. Zitnjak, L. Poulsen, K. Thomsen, C. Qvortrup
Journal: Annals of Oncology (2020)
P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
Authors: S. Ogasawara, J. Llovet, A. El-Khoueiry, A. Vogel, D. Madoff, R. Finn, Z. Ren, K. Modi, J. Li, A. Siegel, L. Dubrovsky, M. Kudo
Journal: Annals of Oncology (2020)
A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Pallawi Torka, Seema Bhat, Kelvin P. Lee, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, AnneMarie W Block, Sheila N. J. Sait, Bora E Baysal, Fadi Habib, Vishala T. Neppalli, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2017)